BC Innovations | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BC Week In Review | Feb 1, 2016
Company News

Thermo Fisher, Samsung Electronics sales and marketing update

Thermo Fisher launched the Samsung IB BRAHMS PCT assay in Europe to diagnose sepsis. The in vitro point-of-care assay detects procalcitonin in whole blood and plasma and has CE Mark approval. The assay is the...
BC Innovations | May 23, 2013
Tools & Techniques

Revisiting adrenomedullin in preeclampsia

A North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in preeclampsia, thereby underscoring adrenomedullin's potential as a marker for the indication. 1 Future studies...
BC Week In Review | Oct 8, 2012
Company News

bioMerieux, Thermo Fisher deal

bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS Procalcitonin (PCT) biomarker on bioMerieux's Vidas immunoassay. The immunoassay, which is performed on bioMerieux's mini Vidas and Vidas systems, is an...
BC Week In Review | Jun 27, 2011
Clinical News

BRAHMS copeptin assay regulatory update

The U.K.'s NICE issued final guidance on Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest pain. The agency said additional...
BC Week In Review | Mar 21, 2011
Clinical News

BRAHMS Copeptin blood test regulatory update

The U.K.'s NICE issued an appraisal consultation document recommending against use of Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest...
BC Week In Review | Nov 2, 2009
Company News

Thermo Fisher sales and marketing update

Thermo Fisher launched its B.R.A.H.M.S. Copeptin blood test in Europe. The price of the blood-based test, which can be combined with a Troponin biomarker test to diagnose acute myocardial infarction (AMI), is undisclosed. Thermo Fisher...
BC Week In Review | Oct 5, 2009
Company News

Brahms, Thermo Fisher deal

Thermo Fisher completed its previously announced acquisition of Brahms for €330 million ($482 million) in cash (see BioCentury, Sept. 14). Brahms AG , Hennigsdorf, Germany   Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass.   Business: Diagnostic...
BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BC Week In Review | Sep 14, 2009
Company News

Brahms, Thermo Fisher deal

Thermo Fisher will acquire diagnostic company Brahms for €330 million ($473 million) in cash. Brahms markets its Procalcitonin (PCT) sepsis diagnostic in Europe and has a development pipeline focused on biomarkers for bacterial infections, cardiovascular...
Items per page:
1 - 10 of 12
BC Innovations | Nov 1, 2019
Product Development

Adrenomed looks beyond immune modulators for sepsis, aims for shock prevention

By targeting a new mechanism further downstream in the sepsis pathway than previous approaches, Adrenomed thinks it can escape the graveyard that has sunk drug development in the indication. Its approach hinges on preventing the...
BC Week In Review | Feb 1, 2016
Company News

Thermo Fisher, Samsung Electronics sales and marketing update

Thermo Fisher launched the Samsung IB BRAHMS PCT assay in Europe to diagnose sepsis. The in vitro point-of-care assay detects procalcitonin in whole blood and plasma and has CE Mark approval. The assay is the...
BC Innovations | May 23, 2013
Tools & Techniques

Revisiting adrenomedullin in preeclampsia

A North Carolina team has shown that fetal deficiency in adrenomedullin resulted in mouse placental abnormalities similar to those found in preeclampsia, thereby underscoring adrenomedullin's potential as a marker for the indication. 1 Future studies...
BC Week In Review | Oct 8, 2012
Company News

bioMerieux, Thermo Fisher deal

bioMerieux and Thermo Fisher extended their non-exclusive 2004 deal to use Thermo Fisher's BRAHMS Procalcitonin (PCT) biomarker on bioMerieux's Vidas immunoassay. The immunoassay, which is performed on bioMerieux's mini Vidas and Vidas systems, is an...
BC Week In Review | Jun 27, 2011
Clinical News

BRAHMS copeptin assay regulatory update

The U.K.'s NICE issued final guidance on Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest pain. The agency said additional...
BC Week In Review | Mar 21, 2011
Clinical News

BRAHMS Copeptin blood test regulatory update

The U.K.'s NICE issued an appraisal consultation document recommending against use of Thermo Fisher's BRAHMS copeptin assay in combination with cardiac troponin testing to rule out myocardial infarction (MI) in patients presenting with acute chest...
BC Week In Review | Nov 2, 2009
Company News

Thermo Fisher sales and marketing update

Thermo Fisher launched its B.R.A.H.M.S. Copeptin blood test in Europe. The price of the blood-based test, which can be combined with a Troponin biomarker test to diagnose acute myocardial infarction (AMI), is undisclosed. Thermo Fisher...
BC Week In Review | Oct 5, 2009
Company News

Brahms, Thermo Fisher deal

Thermo Fisher completed its previously announced acquisition of Brahms for €330 million ($482 million) in cash (see BioCentury, Sept. 14). Brahms AG , Hennigsdorf, Germany   Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass.   Business: Diagnostic...
BioCentury | Sep 21, 2009
Finance

Swiss on a roll

The Swiss biotech space hotted up last week as two of its leading funds, run by HBM Partners, picked up more than $200 million in a couple of trade sale exits, while Evolva S.A. announced...
BC Week In Review | Sep 14, 2009
Company News

Brahms, Thermo Fisher deal

Thermo Fisher will acquire diagnostic company Brahms for €330 million ($473 million) in cash. Brahms markets its Procalcitonin (PCT) sepsis diagnostic in Europe and has a development pipeline focused on biomarkers for bacterial infections, cardiovascular...
Items per page:
1 - 10 of 12